Biochanin A: Understanding the Complexities in the Paradoxical Drug-drug Interaction Potential

Overview

Journal Eur J Drug Metab Pharmacokinet

Date 2015 Apr 24

PMID 25903969

Citations 3

Authors

Nuggehally R Srinivas

Affiliations

Soon will be listed here.

Abstract

Use of dietary products is on the rise due to health benefits associated with the ingestion of flavonoids contained in them. Biochanin A (BioA) is the major constituent of red clover extract and has undergone investigations for health benefits and drug interaction potential. In many instances, BioA has exhibited a clear anomaly in the in vivo pharmacokinetics of co-administered drugs which were contrary to the in vitro studies. The focus of this review is to critically evaluate several mechanisms that may come into play for the interpretation of the in vivo pharmacokinetic data of drugs co-administered with BioA.

Citing Articles

Modified Biochanin A Release from Dual pH- and Thermo-Responsive Copolymer Hydrogels.

Gajic I, Ilic-Stojanovic S, Dinic A, Zdravkovic A, Stanojevic L, Nikolic V Polymers (Basel). 2021; 13(3).

PMID: 33572749 PMC: 7865815. DOI: 10.3390/polym13030426.

Potential Herb-Drug Interactions in the Management of Age-Related Cognitive Dysfunction.

Auxtero M, Chalante S, Abade M, Jorge R, Fernandes A Pharmaceutics. 2021; 13(1).

PMID: 33478035 PMC: 7835864. DOI: 10.3390/pharmaceutics13010124.

Biochanin A alleviates gingival inflammation and alveolar bone loss in rats with experimental periodontitis.

Zhang S, Niu Y, Yang Z, Zhang Y, Guo Q, Yang Y Exp Ther Med. 2020; 20(6):251.

PMID: 33178349 PMC: 7654219. DOI: 10.3892/etm.2020.9381.

References

Azizi R, Goodarzi M, Salemi Z . Effect of biochanin a on serum visfatin level of streptozocin-induced diabetic rats. Iran Red Crescent Med J. 2015; 16(9):e15424. PMC: 4270635. DOI: 10.5812/ircmj.15424. View

Zhang S, Sagawa K, Arnold R, Tseng E, Wang X, Morris M . Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: in vitro and in vivo. J Pharm Sci. 2009; 99(1):430-41. DOI: 10.1002/jps.21827. View

Lucas A, Nation R, Milne R, Reynolds G, Evans A . The effects of phytoestrogenic isoflavones on the formation and disposition of paracetamol sulfate in the isolated perfused rat liver. J Pharm Pharmacol. 2003; 55(5):639-46. DOI: 10.1211/002235703765344540. View

Zhang S, Morris M . Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res. 2003; 20(8):1184-91. DOI: 10.1023/a:1025044913766. View

MIDDLETON Jr E, Kandaswami C, Theoharides T . The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000; 52(4):673-751. View

Wu D, Zhong H, Ding Q, Ba L . Protective effects of biochanin A on articular cartilage: in vitro and in vivo studies. BMC Complement Altern Med. 2014; 14:444. PMC: 4251671. DOI: 10.1186/1472-6882-14-444. View

Martinez-Perez C, Ward C, Cook G, Mullen P, McPhail D, Harrison D . Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer. Biochem Soc Trans. 2014; 42(4):1017-23. DOI: 10.1042/BST20140073. View

Sehdev V, Lai J, Bhushan A . Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells. J Oncol. 2010; 2009:121458. PMC: 2821773. DOI: 10.1155/2009/121458. View

Zhao J, Tang W, Wang J, Xiang J, Gong H, Chen G . Pharmacokinetic and pharmacodynamic studies of four major phytochemical components of Da-Cheng-Qi decoction to treat acute pancreatitis. J Pharmacol Sci. 2013; 122(2):118-27. DOI: 10.1254/jphs.13037fp. View

10.

Hanski L, Genina N, Uvell H, Malinovskaja K, Gylfe A, Laaksonen T . Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation. PLoS One. 2014; 9(12):e115115. PMC: 4267780. DOI: 10.1371/journal.pone.0115115. View

11.

An G, Morris M . Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo. Biopharm Drug Dispos. 2010; 31(5-6):340-50. DOI: 10.1002/bdd.717. View

12.

Jain A, Lai J, Bhushan A . Biochanin A inhibits endothelial cell functions and proangiogenic pathways: implications in glioma therapy. Anticancer Drugs. 2014; 26(3):323-30. DOI: 10.1097/CAD.0000000000000189. View

13.

Hu M, Krausz K, Chen J, Ge X, Li J, Gelboin H . Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab Dispos. 2003; 31(7):924-31. DOI: 10.1124/dmd.31.7.924. View

14.

Moon Y, Sagawa K, Frederick K, Zhang S, Morris M . Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. AAPS J. 2006; 8(3):E433-42. PMC: 2761049. DOI: 10.1208/aapsj080351. View

15.

Shibata C, Ohno M, Otsuka M, Kishikawa T, Goto K, Muroyama R . The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology. 2014; 462-463:42-8. DOI: 10.1016/j.virol.2014.05.024. View

16.

Bhardwaj V, Tadinada S, Jain A, Sehdev V, Daniels C, Lai J . Biochanin A reduces pancreatic cancer survival and progression. Anticancer Drugs. 2013; 25(3):296-302. DOI: 10.1097/CAD.0000000000000044. View

17.

Srinivas N . Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica. 2010; 40(5):357-67. DOI: 10.3109/00498251003663724. View

18.

Kosaka K, Sakai N, Endo Y, Fukuhara Y, Tsuda-Tsukimoto M, Ohtsuka T . Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab Dispos. 2011; 39(9):1495-502. DOI: 10.1124/dmd.111.040030. View

19.

Marin L, Miguelez E, Villar C, Lombo F . Bioavailability of dietary polyphenols and gut microbiota metabolism: antimicrobial properties. Biomed Res Int. 2015; 2015:905215. PMC: 4352739. DOI: 10.1155/2015/905215. View

20.

Shapiro G . Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res. 2004; 10(12 Pt 2):4270s-4275s. DOI: 10.1158/1078-0432.CCR-040020. View